{"id":132077,"date":"2024-08-27T14:50:01","date_gmt":"2024-08-27T09:20:01","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=132077"},"modified":"2024-08-27T14:53:58","modified_gmt":"2024-08-27T09:23:58","slug":"pharma-stock-to-buy-for-an-upside-of-more-than-25-do-you-hold-it","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-for-an-upside-of-more-than-25-do-you-hold-it\/","title":{"rendered":"Pharma stock to buy for an upside of more than 25%; Do you hold it?\u00a0"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-739271847\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>India&#8217;s pharmaceutical sector is a global leader, accounting for 20% of the world&#8217;s generic drug exports. Valued at $50 billion in 2023, the industry is expected to reach $130 billion by 2030. It ranks 3rd globally in volume and 14th in value, driven by strong R&amp;D and manufacturing capabilities.&nbsp;<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-520169197\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><p>With a market capitalization of Rs 12,551.22 crore, the shares of <strong><a href=\"https:\/\/portal.tradebrains.in\/stock\/GLS\/standalone\" target=\"_blank\" rel=\"noreferrer noopener\">Glenmark Life Sciences Ltd<\/a><\/strong> were trading at Rs 1,024.35 per share, decreasing around 0.89 percent as compared to the previous closing price of Rs 1,033.50 apiece.\u00a0<\/p><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Also read<\/strong><\/p>\n\n<figure class=\"wp-block-embed is-type-wp-embed is-provider-trade-brains wp-block-embed-trade-brains\"><div class=\"wp-block-embed__wrapper\">\n<blockquote class=\"wp-embedded-content\" data-secret=\"INbyM3RzH5\"><a href=\"https:\/\/tradebrains.in\/features\/it-stock-hits-20-upper-circuit-after-company-partners-with-microsoft-for-ai-solutions\/\">IT stock hits 20% upper circuit after company partners with Microsoft for AI solutions\u00a0<\/a><\/blockquote><iframe class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" style=\"position: absolute; visibility: hidden;\" title=\"&#8220;IT stock hits 20% upper circuit after company partners with Microsoft for AI solutions\u00a0&#8221; &#8212; Trade Brains\" src=\"https:\/\/tradebrains.in\/features\/it-stock-hits-20-upper-circuit-after-company-partners-with-microsoft-for-ai-solutions\/embed\/#?secret=NoeNqsRtIx#?secret=INbyM3RzH5\" data-secret=\"INbyM3RzH5\" width=\"600\" height=\"338\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\"><\/iframe>\n<\/div><\/figure><\/blockquote><p>Looking into Glenmark Life Sciences&#8217;s performance, revenue increased by 2 percent from Rs 578 crore in Q1FY24 to Rs 589 crore in Q1FY25. During the same period, net profit decreased by 17 percent, from Rs 135 crore to Rs 111 crore.&nbsp;<\/p><p><strong>ICICI Direct, one of the well-known brokerages in India, gave a \u2018Buy\u2019 call on the pharma stock with a target price of Rs 1,295 apiece, indicating a potential upside of 26 percent from Tuesday&#8217;s price of Rs 1,024.35 per share.&nbsp;<\/strong><\/p><div class=\"trade-content_5\" id=\"trade-794160455\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p><strong>Here is the rationale behind the bullish potential upside of 26%:&nbsp;<\/strong><\/p><p>\u25cf Revenue Growth: In Q1FY25, the company&#8217;s revenues grew by 5% YoY and 11% QoQ to \u20b9589 crore, driven by a 10% YoY and 7% QoQ increase in non-GPL API sales, and an 18% QoQ rise in API sales to Glenmark Pharma.&nbsp;<\/p><p>\u25cf Profit and EBITDA Improvement: Despite a YoY decline, EBITDA and PAT showed solid sequential recovery, growing 13% and 14% QoQ to \u20b9160 crore and \u20b9112 crore, respectively, indicating positive momentum under the new management.&nbsp;<\/p><p>\u25cf Capacity Expansion: GLS plans to invest \u20b9700 crore over two years to increase reactor capacity to 1424 KL by FY25 and 2644 KL by FY27, including 400 KL for backward integration, positioning the company for significant growth from FY26 onwards.&nbsp;<\/p><p>\u25cf CDMO and Niche Products Growth: The CDMO business is expanding with two new projects expected in H2FY25, while the niche HP API portfolio now includes 20 products, targeting a substantial US$ 40 billion market, driving future growth.&nbsp;<\/p><p>Glenmark Life Sciences Limited is principally in the business of developing, manufacturing, and distributing active pharmaceutical ingredients (API). The Company&#8217;s product portfolio includes several therapeutic categories, such as cardiovascular (CVS) illness, central nervous system (CNS) diseases, and anti-infectives.&nbsp;<\/p><div class=\"trade-content-10\" id=\"trade-3397851425\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_3_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"2969612066\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Written by:- Abhishek Singh<\/strong><\/p><\/blockquote><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Also read<\/strong><\/p>\n\n<figure class=\"wp-block-embed is-type-wp-embed is-provider-trade-brains wp-block-embed-trade-brains\"><div class=\"wp-block-embed__wrapper\">\n<blockquote class=\"wp-embedded-content\" data-secret=\"jufkff6hy7\"><a href=\"https:\/\/tradebrains.in\/features\/stocks-out-of-asm-stage-1-to-keep-an-eye-on\/\">Stocks out of ASM stage 1 to keep an eye on<\/a><\/blockquote><iframe class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" style=\"position: absolute; visibility: hidden;\" title=\"&#8220;Stocks out of ASM stage 1 to keep an eye on&#8221; &#8212; Trade Brains\" src=\"https:\/\/tradebrains.in\/features\/stocks-out-of-asm-stage-1-to-keep-an-eye-on\/embed\/#?secret=wJ5HSAohzT#?secret=jufkff6hy7\" data-secret=\"jufkff6hy7\" width=\"600\" height=\"338\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\"><\/iframe>\n<\/div><\/figure><\/blockquote><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Disclaimer<\/strong><\/h2><div class=\"wp-block-image\"><figure class=\"aligncenter size-medium\"><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/warning-disclaimer-300x300.png\" alt=\"\" class=\"wp-image-26306\"\/><\/figure><\/div><p><strong>The views and investment tips expressed by investment experts\/broking houses\/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.<\/strong><\/p><div class=\"trade-after-content\" id=\"trade-4281314746\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>India&#8217;s pharmaceutical sector is a global leader, accounting for 20% of the world&#8217;s generic drug exports. Valued at $50 billion in 2023, the industry is expected to reach $130 billion by 2030. It ranks 3rd globally in volume and 14th in value, driven by strong R&amp;D and manufacturing capabilities.&nbsp; With a market capitalization of Rs [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":111747,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[31,1789],"tags":[11115,11114,21962,6616,20792,948,936],"class_list":["post-132077","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-trending-news","tag-glenmark-life-sciences-latest-news","tag-glenmark-life-sciences-share-price","tag-glenmark-life-sciences-share-target-2024","tag-pharma-stock","tag-pharma-stock-to-buy","tag-stock-market","tag-stock-market-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma stock to buy for an upside of more than 25%; Do you hold it?\u00a0 - Trade Brains Features<\/title>\n<meta name=\"description\" content=\"India&#039;s pharmaceutical sector is a global leader, accounting for 20% of the world&#039;s generic drug exports. Valued at $50 billion in 2023, the industry is expected to reach $130 billion by 2030. It ranks 3rd globally in volume and 14th in value, driven by strong R&amp;D and manufacturing capabilities.\u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-for-an-upside-of-more-than-25-do-you-hold-it\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma stock to buy for an upside of more than 25%; Do you hold it?\u00a0\" \/>\n<meta property=\"og:description\" content=\"India&#039;s pharmaceutical sector is a global leader, accounting for 20% of the world&#039;s generic drug exports. Valued at $50 billion in 2023, the industry is expected to reach $130 billion by 2030. It ranks 3rd globally in volume and 14th in value, driven by strong R&amp;D and manufacturing capabilities.\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-for-an-upside-of-more-than-25-do-you-hold-it\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-27T09:20:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-27T09:23:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-for-an-upside-of-more-than-25-do-you-hold-it\/\",\"url\":\"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-for-an-upside-of-more-than-25-do-you-hold-it\/\",\"name\":\"Pharma stock to buy for an upside of more than 25%; Do you hold it?\u00a0 - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-for-an-upside-of-more-than-25-do-you-hold-it\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-for-an-upside-of-more-than-25-do-you-hold-it\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\",\"datePublished\":\"2024-08-27T09:20:01+00:00\",\"dateModified\":\"2024-08-27T09:23:58+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"description\":\"India's pharmaceutical sector is a global leader, accounting for 20% of the world's generic drug exports. Valued at $50 billion in 2023, the industry is expected to reach $130 billion by 2030. It ranks 3rd globally in volume and 14th in value, driven by strong R&D and manufacturing capabilities.\u00a0\",\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-for-an-upside-of-more-than-25-do-you-hold-it\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-for-an-upside-of-more-than-25-do-you-hold-it\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-for-an-upside-of-more-than-25-do-you-hold-it\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-for-an-upside-of-more-than-25-do-you-hold-it\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma stock to buy for an upside of more than 25%; Do you hold it?\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma stock to buy for an upside of more than 25%; Do you hold it?\u00a0 - Trade Brains Features","description":"India's pharmaceutical sector is a global leader, accounting for 20% of the world's generic drug exports. Valued at $50 billion in 2023, the industry is expected to reach $130 billion by 2030. It ranks 3rd globally in volume and 14th in value, driven by strong R&D and manufacturing capabilities.\u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-for-an-upside-of-more-than-25-do-you-hold-it\/","og_locale":"en_US","og_type":"article","og_title":"Pharma stock to buy for an upside of more than 25%; Do you hold it?\u00a0","og_description":"India's pharmaceutical sector is a global leader, accounting for 20% of the world's generic drug exports. Valued at $50 billion in 2023, the industry is expected to reach $130 billion by 2030. It ranks 3rd globally in volume and 14th in value, driven by strong R&D and manufacturing capabilities.\u00a0","og_url":"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-for-an-upside-of-more-than-25-do-you-hold-it\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2024-08-27T09:20:01+00:00","article_modified_time":"2024-08-27T09:23:58+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-for-an-upside-of-more-than-25-do-you-hold-it\/","url":"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-for-an-upside-of-more-than-25-do-you-hold-it\/","name":"Pharma stock to buy for an upside of more than 25%; Do you hold it?\u00a0 - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-for-an-upside-of-more-than-25-do-you-hold-it\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-for-an-upside-of-more-than-25-do-you-hold-it\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","datePublished":"2024-08-27T09:20:01+00:00","dateModified":"2024-08-27T09:23:58+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"description":"India's pharmaceutical sector is a global leader, accounting for 20% of the world's generic drug exports. Valued at $50 billion in 2023, the industry is expected to reach $130 billion by 2030. It ranks 3rd globally in volume and 14th in value, driven by strong R&D and manufacturing capabilities.\u00a0","breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-for-an-upside-of-more-than-25-do-you-hold-it\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-for-an-upside-of-more-than-25-do-you-hold-it\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-for-an-upside-of-more-than-25-do-you-hold-it\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-for-an-upside-of-more-than-25-do-you-hold-it\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Pharma stock to buy for an upside of more than 25%; Do you hold it?\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/132077","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=132077"}],"version-history":[{"count":2,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/132077\/revisions"}],"predecessor-version":[{"id":132082,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/132077\/revisions\/132082"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/111747"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=132077"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=132077"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=132077"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}